M
Maria Eugenia Guicciardi
Researcher at Mayo Clinic
Publications - 52
Citations - 5444
Maria Eugenia Guicciardi is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Apoptosis & Liver injury. The author has an hindex of 27, co-authored 52 publications receiving 4927 citations. Previous affiliations of Maria Eugenia Guicciardi include University of Modena and Reggio Emilia.
Papers
More filters
Journal ArticleDOI
Free fatty acids promote hepatic lipotoxicity by stimulating TNF‐α expression via a lysosomal pathway
Ariel E. Feldstein,Nathan W. Werneburg,Ali Canbay,Maria Eugenia Guicciardi,Steven F. Bronk,Robert Rydzewski,Laurence J. Burgart,Gregory J. Gores +7 more
TL;DR: In a dietary murine model of NAFLD, either genetic or pharmacological inactivation of ctsb protected against development of hepatic steatosis, liver injury, and insulin resistance with its associated “dysmetabolic syndrome.”
Journal ArticleDOI
Lysosomes in cell death
TL;DR: This review focuses on the players and the molecular mechanisms involved in the lysosomal pathway of apoptosis as well as on the importance of this pathway in development and pathology.
Journal ArticleDOI
Life and death by death receptors
TL;DR: Insights into these various death receptor signaling pathways provide new therapeutic strategies targeting these receptors in pathophysiological processes, including regulation of cell proliferation and differentiation, chemokine production, inflammatory responses, and tumor‐promoting activities.
Journal ArticleDOI
Hepatocyte Death: A Clear and Present Danger
TL;DR: The hepatocyte is especially vulnerable to injury due to its central role in xenobiotic metabolism including drugs and alcohol, participation in lipid and fatty acid metabolism, its unique role in the enterohepatic circulation of bile acids, and the widespread prevalence of hepatotropic viruses.
Journal ArticleDOI
Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice
Ariel E. Feldstein,Ali Canbay,Maria Eugenia Guicciardi,Hajime Higuchi,Steven F. Bronk,Gregory J. Gores +5 more
TL;DR: F Fas is implicate as a link between obesity associated fatty liver and increased susceptibility to liver damage and upregulated Fas expression and more sensitive to apoptosis by a Fas agonist are implicate.